Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
03/2000
03/21/2000US6040159 Nucleotide sequence of ribonucleotides and optionally deoxyribonucleotides with optionally modified phosphates and hydrogen bonded to itself; targeted against tumor necrosis factor; for antiarthritic agents, antisense agents, viricides
03/21/2000US6040148 Heat shock protein/antigen having molecular weight of about 86 kilodaltons which induces an antibody to a breakdown product in recovering patients; for immunoassay diagnosis, immunogens and bactericides with reduced side effects
03/21/2000US6040145 Potentiation of the immune response
03/21/2000US6040133 D-enzyme compositions and methods of their use
03/21/2000US6039981 Itraconazole, phosphoric acid with carriers as fungicides
03/21/2000US6039969 Immune response modifier compounds for treatment of TH2 mediated and related diseases
03/21/2000US6039963 Ceramide compounds, process for their preparation and use
03/21/2000US6039959 Treatment and diagnosis of infections due to helicobacter pylori
03/21/2000US6039958 Stabilized live vaccine
03/21/2000US6039684 Non-lethal conditioning methods for the treatment of acquired immunodeficiency syndrome
03/21/2000CA1340931C Infectious bural disease virus
03/16/2000WO2000014274A1 Method for the identification and speciation of bacteria of the burkholderia cepacia complex
03/16/2000WO2000014244A2 Treatment of cervical cancer
03/16/2000WO2000014240A2 Attenuated salmonella sp12 mutants as antigen carriers
03/16/2000WO2000014235A1 Kunitz domain polypeptide zkun6
03/16/2000WO2000014230A1 Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof
03/16/2000WO2000014220A1 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus
03/16/2000WO2000014217A2 G-motif oligonucleotides and uses thereof
03/16/2000WO2000014200A2 Essential bacterial genes and their use
03/16/2000WO2000014112A2 Papillomaviruses, means for the detection thereof and therapy for diseases caused thereby
03/16/2000WO2000014100A1 Nocathiacin antibiotic derivatives prepared by microbial biotransformation
03/16/2000WO2000014086A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000WO2000014063A1 Therapeutic compounds and methods
03/16/2000WO2000014054A1 Unsaturated hydroximic acid derivatives as parp inhibitors
03/16/2000WO2000013708A1 Methods for treating or preventing viral infections and associated diseases
03/16/2000WO2000013707A1 Preventives/remedies for multiple organ failure
03/16/2000WO2000013697A1 Tear grass-derived antibacterial agent and process for producing the same
03/16/2000WO2000013695A1 Pharmaceutical preparation and method of treatment
03/16/2000WO2000013694A1 Gcp
03/16/2000WO2000013649A2 Use of lithium gluconate for making a medicine for treating herpes and seborrheic dermatitis
03/16/2000WO2000002881A3 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein
03/16/2000WO2000002582A3 Treatment of celiac disease with interleukin-15 antagonists
03/16/2000WO2000000500A3 Polyketides and their synthesis
03/16/2000WO2000000216A3 Use of poxviruses as enhancer of specific immunity
03/16/2000WO1999067286A3 Novel staphylococcus peptides for bacterial interference
03/16/2000WO1999064047A9 Novel antiviral compounds
03/16/2000WO1999063929A9 Multibinding inhibitors of microsomal triglyceride transferase protein
03/16/2000WO1999061471A3 Human transmembrane proteins
03/16/2000CA2343522A1 Methods for treating or preventing viral infections and associated diseases
03/16/2000CA2342898A1 Unsaturated hydroximic acid derivatives as parp inhibitors
03/16/2000CA2342882A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000CA2342862A1 Nocathiacin antibiotic derivatives prepared by microbial biotransformation
03/16/2000CA2342858A1 Method of screening compounds useful in the treatment of a desease caused by or exacerbated by mpv
03/16/2000CA2342796A1 Preventives/remedies for multiple organ failure
03/16/2000CA2341782A1 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus
03/16/2000CA2341349A1 Attenuated cells comprising sp12 mutants, carriers and compositions containing same, methods of production and uses thereof
03/16/2000CA2341338A1 G-motif oligonucleotides and uses thereof
03/16/2000CA2340686A1 Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof
03/16/2000CA2309212A1 Essential bacterial genes and their use
03/15/2000EP0985679A1 New hydroxy derivatives of tylosin and process for their preparation
03/15/2000EP0985052A1 METHODS AND COMPOSITIONS TO IDENTIFY SWINE GENETICALLY RESISTANT TO F18 $i(E. COLI) ASSOCIATED DISEASES
03/15/2000EP0985046A1 A soluble vaccinia virus protein that binds chemokines
03/15/2000EP0985040A1 Preparation of glycosylated tumor necrosis factor
03/15/2000EP0985015A1 Disinfecting compositions and processes for disinfecting surfaces
03/15/2000EP0984975A1 Multicyclic erythromycin derivatives
03/15/2000EP0984967A1 Naphthyridine derivatives and their analogues inhibiting cytomegalovirus
03/15/2000EP0984955A1 SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNF$g(a) LEVELS
03/15/2000EP0984947A1 Oxazolidinone antibacterial agents having a thiocarbonyl functionality
03/15/2000EP0984790A1 Herpes simplex virus vp22 vaccines and methods of use
03/15/2000EP0984774A1 Gastroretentive controlled release microspheres for improved drug delivery
03/15/2000EP0806943B1 Valaciclovir tablets containing colloidal silicon dioxide
03/15/2000EP0797579B1 Erythromycin a 9-0-oxime derivatives endowed with antibiotic activity
03/15/2000EP0667351B1 Compound uch9
03/15/2000EP0653939B1 Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
03/15/2000EP0567566B1 Methods for treating tumor necrosis factor mediated diseases
03/15/2000EP0563311B1 Improved vaccines
03/15/2000EP0549702B1 Use of recombinant colony stimulating factor-1
03/15/2000EP0434721B1 Viral nucleotide sequences
03/15/2000CN1247531A Arylsulfonyl hydroxamic acid derivatives
03/15/2000CN1247090A Infectious cloacal bursa virus vaccine for chicken and its preparing process and application
03/15/2000CN1247079A Immersed-in-wine Chinese medicine for preventing and curing AIDS
03/15/2000CN1247063A Ear drops
03/15/2000CN1050302C Chicken anaemia agent vaccine
03/15/2000CN1050283C Gel-type cosmetic composite
03/14/2000US6037488 Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
03/14/2000US6037470 Purine compounds having PDE IV inhibitory activity and methods of synthesis
03/14/2000US6037469 Beta lactamase inhibitor and antibacterial; for treating bacterial infections in humans and animals
03/14/2000US6037467 Methods for preparing carbohydrate-containing hydrophilic polymers
03/14/2000US6037461 FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
03/14/2000US6037448 Chimeric viral protein with human lymphocyte determinant; for vaccine development against infection
03/14/2000US6037386 Latex barrier having polymer matrix comprising zinc oxide or zinc gluconate gel irritant deactivating agent; condoms, gloves
03/14/2000US6037376 Methods for therapy of cancer
03/14/2000US6037369 Administering caffeic acid or b-(3,4-dihydroxyphenyl)-lactic acid conjugate
03/14/2000US6037351 Method of inhibiting hepatitis B virus
03/14/2000US6037348 Inhibition of viral replication
03/14/2000US6037341 Carbapenem derivatives
03/14/2000US6037323 Peptides and peptide analogues that mimic the structural and pharmacological properties of human apoa-i; treating disorders associated with dyslipoproteinemia, including hypercholesterolemia, cardiovascular disease, atherosclerosis,
03/14/2000US6037322 Beneficial in preventing the local extension of the microvascular and macrovascular occluding arterial thrombus, thereby reducing the neurological deficit resulting from the stroke; administered by continuous infusion
03/14/2000US6037157 Method for improving pharmacokinetics
03/14/2000US6037146 CDNA clone HE8CH90 that encodes a novel 7-transmembrane receptor
03/14/2000US6036960 Filamentous hemagglutinin of B. pertussis
03/14/2000US6036959 HCMV/HSV fusion glycoproteins
03/14/2000US6036953 Dna encoding with escherichia coli and fusion polypeptides
03/14/2000CA2281852A1 An antifungal lactone compound
03/14/2000CA2132424C Antisense oligonucleotide inhibition of papillomavirus
03/14/2000CA2071205C Cell surface antigen associated with cellular apoptosis
03/14/2000CA1340926C Human rhinovirus peptides
03/09/2000WO2000012741A2 Inducible expression system
03/09/2000WO2000012738A1 Targeted adenovirus vectors for delivery of heterologous genes
03/09/2000WO2000012720A2 Elongase genes and uses thereof
1 ... 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 ... 1798